BCL-X
BCL-XL
Drug resistance
KRASG12C
PROTAC
Sotorasib
Journal
Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937
Informations de publication
Date de publication:
09 03 2022
09 03 2022
Historique:
received:
05
01
2022
accepted:
19
02
2022
entrez:
9
3
2022
pubmed:
10
3
2022
medline:
13
4
2022
Statut:
epublish
Résumé
KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent inhibitor of KRAS
Identifiants
pubmed: 35260176
doi: 10.1186/s13045-022-01241-3
pii: 10.1186/s13045-022-01241-3
pmc: PMC8905794
doi:
Substances chimiques
bcl-X Protein
0
DT2216
0
KRAS protein, human
0
Piperazines
0
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Pyridines
0
Pyrimidines
0
sotorasib
2B2VM6UC8G
Types de publication
Letter
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
23Subventions
Organisme : NCI NIH HHS
ID : R01 CA242003
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: Is the undruggable drugged? Nat Rev Drug Discov. 2020;19(8):533–52.
doi: 10.1038/s41573-020-0068-6
Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217–23.
doi: 10.1038/s41586-019-1694-1
Ryan MB, Fece de la Cruz F, Phat S, Myers DT, Wong E, Shahzade HA, et al. Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS. Clin Cancer Res. 2020;26(7):1633–43.
Misale S, Fatherree JP, Cortez E, Li C, Bilton S, Timonina D, et al. KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition. Clin Cancer Res. 2019;25(2):796–807.
doi: 10.1158/1078-0432.CCR-18-0368
Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128(6):1173–86.
doi: 10.1016/j.cell.2007.01.037
Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 2007;14(5):943–51.
doi: 10.1038/sj.cdd.4402081
Schoenwaelder SM, Jarman KE, Gardiner EE, Hua M, Qiao J, White MJ, et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood. 2011;118(6):1663–74.
doi: 10.1182/blood-2011-04-347849
Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, et al. A selective BCL-X L PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25(12):1938–47.
doi: 10.1038/s41591-019-0668-z
He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S, et al. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. J Hematol Oncol. 2020;13(1):95.
doi: 10.1186/s13045-020-00928-9
Zhang X, Thummuri D, Liu X, Hu W, Zhang P, Khan S, et al. Discovery of PROTAC BCL-X L degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020;192:112186.
doi: 10.1016/j.ejmech.2020.112186
Kasper S, Breitenbuecher F, Reis H, Brandau S, Worm K, Köhler J, et al. Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade. Oncogene. 2013;32(23):2873–81.
doi: 10.1038/onc.2012.302
Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G, et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene. 2003;22(43):6785–93.
doi: 10.1038/sj.onc.1206792